Apple has so far made two payments of €4.5 billion (US$5.2 billion) into an escrow account for the €13 billion (US$15.1 billion) in back taxes the European Commission has ordered it to pay Ireland, according to new regulatory filings.
“As of June 30, 2018, €4.5 billion (US$5.2 billion) of the recovery amount was funded into escrow. Subsequent to June 30, 2018, the company has funded an additional €4.5 billion (US$5.2 billion) of the recovery amount into escrow,” Apple stated in quarterly documents reported by Reuters.
Apple and the Irish government set up an escrow account rather than direct payments in anticipation of an appeal against the European Commission, which could begin this fall. The fight could stretch out for several years however with no guarantee of success, since the Commission has previously ruled against other multinational corporations accused of violating European tax rules.
In August 2016, the Commission ruled that Ireland had extended preferential tax deals to Apple for years, something considered illegal state aid under European law—aid offered to one company must be extended to others as well. The EU argued that the Irish government had even reverse-engineered rules to appease Apple.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan